Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIFY: glofitamab with rituximab-CHOP or obinutuzumab-CHOP for untreated Richter syndrome
2022-501554-11-00Phase 2Authorised
- Sponsor
- French Innovative Leukemia Organization
- Start
- Aug 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of glofitamab in Richter's syndrome (RS), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by French Innovative Leukemia Organization. Primary endpoint: Complete metabolic response rate. Planned start Aug 2023; status: authorised.
02
Drugs
glofitamab
03
Conditions
Richter's syndrome (RS)diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2022-501554-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501554-11-00.